Roche ECTRIMS 2015: how big can ocrelizumab be?

BUY, Fair Value CHF327 (+26%)
News published on October Wednesday 7, 2015
Share on

Ahead of the OPERA I & II and the ORATORIO fully-detailed data to be presented at the ECTRIMS medical congress starting today, we summarize what is at stake for ocrelizumab and Roche. Our base case suggests peak sales of USD3bn with 80% PoS. Under certain conditions, and depending on the price set for the drug to best leverage its potential in RRMS and PPMS, this figure could be higher.


For more information, please contact marketing@bryangarnier.com 

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities